Stroke and vascular neurology · 2026
Effectiveness and safety of tenecteplase for acute ischaemic stroke at primary stroke centres: a multicentre retrospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Jingjing, Fan Yuhua, Liu Yu, Zhang Jian, Dang Chao, Xing Shihui, Zeng Jinsheng, TNK-STONE Collaborators
Аннотация
BACKGROUND: Evidence regarding tenecteplase (TNK) use at primary stroke centres (PSCs) remains limited. PSCs often serve as the initial or sole point of care for acute ischaemic stroke (AIS) patients. We aimed to assess the effectiveness and safety of TNK at PSCs.
METHODS: Consecutive AIS patients receiving TNK or alteplase within 4.5 hours at PSCs in China from 1 January to 31 December 2023 were included retrospectively. Propensity score matching (PSM) was used to match TNK-treated and alteplase-treated patients 1:1 and their effectiveness and safety were compared. The primary effectiveness outcome was modified Rankin Scale (mRS) 0-1 at 90 days, while the key safety outcome was post-thrombolysis symptomatic intracranial haemorrhage (sICH).
RESULTS: We included 4000 cases from 62 PSCs (TNK: 1670; alteplase: 2330). After PSM, 1552 cases per group were analysed. There was no significant difference between the two groups in the proportion of patients achieving mRS 0-1 at 90 days (69.7% vs 70.9%, p=0.472). No differences in functional outcome or sICH were observed in adjusted analyses. Exploratory subgroup analyses suggested a potential association between TNK and improved outcomes in patients with large artery atherosclerosis (LAA).
CONCLUSIONS: TNK showed comparable effectiveness and safety to alteplase for AIS patients at PSCs. Exploratory subgroup findings in LAA require confirmation in future prospective studies.
METHODS: Consecutive AIS patients receiving TNK or alteplase within 4.5 hours at PSCs in China from 1 January to 31 December 2023 were included retrospectively. Propensity score matching (PSM) was used to match TNK-treated and alteplase-treated patients 1:1 and their effectiveness and safety were compared. The primary effectiveness outcome was modified Rankin Scale (mRS) 0-1 at 90 days, while the key safety outcome was post-thrombolysis symptomatic intracranial haemorrhage (sICH).
RESULTS: We included 4000 cases from 62 PSCs (TNK: 1670; alteplase: 2330). After PSM, 1552 cases per group were analysed. There was no significant difference between the two groups in the proportion of patients achieving mRS 0-1 at 90 days (69.7% vs 70.9%, p=0.472). No differences in functional outcome or sICH were observed in adjusted analyses. Exploratory subgroup analyses suggested a potential association between TNK and improved outcomes in patients with large artery atherosclerosis (LAA).
CONCLUSIONS: TNK showed comparable effectiveness and safety to alteplase for AIS patients at PSCs. Exploratory subgroup findings in LAA require confirmation in future prospective studies.